Tirzepatide and semaglutide are two of the most popular weight-loss drugs on the market
Tirzepatide and semaglutide are two of the most popular weight-loss drugs on the market. Both drugs have been proven to be highly effective in clinical trials, and they offer a variety of benefits for those who are looking to lose weight. Tirzepatide is a once-weekly injection that has been shown to help people lose up to 25% of their body weight in 28 weeks (average weight loss of 52 lb), while Semaglutide has been shown to help people lose up to 12.5% of their body weight. Both drugs are FDA-approved and backed by years of research. Tirzepatide and semaglutide are safe and effective options for those who are looking to lose weight.
They both work in similar ways, but there are some key differences
Tirzepatide and semaglutide are two drugs that are highly effective at helping individuals lose pounds of body fat in a relatively short period of time. Both tirzepatide and semaglutide are glucagon-like peptide 1 (GLP-1) receptor agonists, however tirzepatide is also a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) both result in similar activity; increasing insulin sensitivity, triglyceride clearance, lipolysis (fat utilization for fuel) and metabolic rate (metabolism), and decreasing appetite, fat storage and rate of digestion. Due to it’s dual action on Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), tirzepatide is more effective than semaglutide at promoting weight loss, but both drugs are associated with a significant reduction in body weight. However, both tirzepatide and semaglutide are associated with equal efficacy on lowering blood sugar levels and risk of side effects such as nausea and vomiting.
Tirzepatide is a newer drug, so there is less data available on it
Tirzepatide is a newer drug that was FDA approved in 2022 that promotes weight-loss via GLP-1 receptor and GIP receptor agonism. It works by increasing insulin sensitivity, triglyceride clearance, lipolysis (fat utilization for fuel) and metabolic rate (metabolism), and decreasing appetite, fat storage and rate of digestion. Tirzepatide is injected subcutaneously once weekly, and the most common side effects include nausea, vomiting, diarrhea, headache, and injection site reactions. Tirzepatide should not be used in people with a history of pancreatitis or medullary thyroid cancer. Tirzepatide is a newer drug, so there is less data available on it than semaglutide; however, the available data shows that it can be up to 2x more effective than similar treatment with semaglutide. Tirzepatide may cause side effects, but the majority of people tolerate it well.
Tirzepatide has been shown to be more effective in reducing weight and body fat
Tirzepatide is a new weight-loss medication that has been shown to be more effective than semaglutide, another popular GLP-1 agonist. Tirzepatide is a dual agonist of both GLP-1 and GIP, while semaglutide is only a GLP-1 agonist. In a clinical trial of 3,731 patients, those who took tirzepatide lost an average of 11.5% of their body weight, while those who took semaglutide lost an average of 9.2% of their body weight. Tirzepatide is also more effective in reducing abdominal fat and triglycerides. These results suggest that tirzepatide is a more effective weight-loss medication than semaglutide and could help more people achieve their weight-loss goals.
If you’re considering a weight-loss drug, tirzepatide and semaglutide are two of the most popular options on the market. They both work in similar ways, but tirzepatide has been shown to be more effective in reducing weight and body fat. However, semaglutide has been around for longer and may have fewer side effects. If you feel that your extra weight is impacting your health and quality of life, please reach out to the Valhalla Vitality team to see if one of these medications could be right for you.
Works Cited
- Pleiotropic actions of glucagon-like polypeptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) in type 2 diabetes. Reprinted from Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410–421. Creative Commons license and disclaimer available from: https://creativecommons.org/licenses/by/4.0/legalcode.25 intended).
- Rizvi AA, Rizzo M. The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. Diabetes Metab Syndr Obes. 2022 Apr 5;15:1023-1030. doi: 10.2147/DMSO.S351982. PMID: 35411165; PMCID: PMC8994606.
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
- Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982. doi:10.1001/jamanetworkopen.2022.31982
- Bray GA, Ryan DH. Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes. Diabetes Obes Metab. 2021;23(suppl 1):50-62. doi:10.1111/dom.14200
